Substance Abuse disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SBS003 MIFTS: 51	Substance Abuse Categories: Mental diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse ¹¹ ²⁸ ¹⁴ ⁷⁵

Substance-Related Disorders ⁴³ ⁷¹

Substance Abuse Problem ⁷¹

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:302

MeSH ⁴³ D019966

NCIt ⁴⁹ C16522

SNOMED-CT ⁶⁸ 26416006

UMLS ⁷¹ C0013146 C0236969 C0740858

Sources

Summaries for Substance Abuse

Disease Ontology: ¹¹ A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary: Substance Abuse, also known as substance-related disorders, is related to cannabis abuse and antisocial personality disorder, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Tamoxifen metabolism and Neurotransmitter clearance. The drugs Olanzapine and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cingulate cortex, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: ⁷⁵ Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods which are... more...

Sources

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 525)

#	Related Disease	Score	Top Affiliating Genes
1	cannabis abuse	32.5	SLC6A4 PRODH DRD2 COMT BDNF
2	antisocial personality disorder	32.5	SLC6A4 SLC6A3 PRL GABRA2 DRD2 COMT
3	opioid abuse	32.5	OPRM1 DRD2 CYP2D6 CCR6 CCR5
4	eating disorder	32.4	SLC6A4 SLC6A3 OPRM1 H2AC18 DRD2 COMT
5	bipolar disorder	32.4	SLC6A4 SLC6A3 PRODH PRL OPRM1 GABRA2
6	alcohol use disorder	32.3	TF SLC6A4 SLC6A3 SERPINA3 PRODH OPRM1
7	cocaine abuse	32.3	SLC6A4 SLC6A3 OPRM1 H2AC18 DRD3 DRD2
8	schizoaffective disorder	32.3	SLC6A4 SERPINA3 PRODH PRL DRD3 DRD2
9	amphetamine abuse	32.2	SLC6A4 SLC6A3
10	schizophrenia	32.1	SLC6A4 SLC6A3 SERPINA3 PRODH PRL OPRM1
11	post-traumatic stress disorder	32.0	SLC6A4 SLC6A3 H2AC18 DRD2 COMT BDNF
12	personality disorder	31.9	SLC6A4 SLC6A3 PRL DRD3 DRD2 COMT
13	polysubstance abuse	31.9	DRD3 DRD2 COMT
14	alcohol dependence	31.8	TF SLC6A4 SLC6A3 SERPINA3 OPRM1 H2AC18
15	conduct disorder	31.7	SLC6A4 SLC6A3 GABRA2 DRD2 COMT
16	disease of mental health	31.7	SLC6A4 SLC6A3 SERPINA3 PRODH OPRM1 H2AC18
17	drug dependence	31.7	SLC6A4 SLC6A3 OPRM1 GABRA2 DRD3 DRD2
18	substance dependence	31.6	SLC6A4 SLC6A3 SERPINA3 OPRM1 H2AC18 GABRA2
19	chronic pain	31.6	OPRM1 COMT BDNF
20	opiate dependence	31.5	SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 COMT
21	major depressive disorder	31.5	SLC6A4 SLC6A3 PRL OPRM1 DRD3 DRD2
22	anxiety	31.5	SLC6A4 SLC6A3 PRODH PRL OPRM1 GABRA2
23	tobacco addiction	31.5	SLC6A4 SLC6A3 OPRM1 H2AC18 GABRA2 DRD3
24	attention deficit-hyperactivity disorder	31.5	SLC6A4 SLC6A3 SERPINA3 PRODH OPRM1 H2AC18
25	psychotic disorder	31.5	SLC6A4 SLC6A3 SERPINA3 PRODH PRL OPRM1
26	bulimia nervosa	31.4	SLC6A4 SLC6A3 DRD2 COMT BDNF
27	borderline personality disorder	31.4	SLC6A4 SLC6A3 PRL DRD2 COMT BDNF
28	mood disorder	31.4	SLC6A4 SLC6A3 SERPINA3 PRODH H2AC18 DRD3
29	panic disorder	31.3	SLC6A4 SLC6A3 PRL DRD3 DRD2 COMT
30	cocaine dependence	31.3	SLC6A4 SLC6A3 PRL OPRM1 GABRA2 DRD3
31	anorexia nervosa	31.2	SLC6A4 PRL DRD2 COMT BDNF
32	pathological gambling	31.2	SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 COMT
33	learning disability	31.1	PRODH H2AC18 COMT BDNF
34	viral infectious disease	31.1	SERPINA3 H2AC18 CCR6 CCR5
35	adjustment disorder	31.1	SLC6A4 CYP2D6 BDNF
36	generalized anxiety disorder	31.1	SLC6A4 PRODH H2AC18 DRD2 CYP2D6 COMT
37	cannabis dependence	31.0	GABRA2 DRD2 COMT
38	sleep disorder	31.0	SLC6A4 SLC6A3 H2AC18 COMT BDNF
39	neonatal abstinence syndrome	30.9	OPRM1 CYP2D6 COMT
40	dystonia	30.9	SLC6A3 PRL DRD3 DRD2 CYP2D6 COMT
41	gilles de la tourette syndrome	30.9	SLC6A4 SLC6A3 DRD3 DRD2 COMT BDNF
42	dysthymic disorder	30.9	SLC6A4 SLC6A3 PRODH CYP2D6 COMT BDNF
43	bipolar i disorder	30.9	SLC6A4 PRODH PRL DRD2 CYP2D6 COMT
44	tardive dyskinesia	30.9	DRD2 CYP2D6 COMT
45	social phobia	30.9	SLC6A4 SLC6A3 SERPINA3 PRODH PRL DRD2
46	neurotic disorder	30.9	SLC6A4 COMT BDNF
47	sexual health disorder	30.9	SLC6A4 PRL H2AC18
48	obsessive-compulsive disorder	30.9	SLC6A4 SLC6A3 PRL DRD3 DRD2 CYP2D6
49	human immunodeficiency virus infectious disease	30.9	SERPINA3 H2AC18 CCR6 CCR5
50	withdrawal disorder	30.9	SLC6A4 SLC6A3 OPRM1 DRD2 CYP2D6 BDNF

Graphical network of the top 20 diseases related to Substance Abuse:

Sources

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:

symptoms

MGI Mouse Phenotypes related to Substance Abuse:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.13	ABCB7 BDNF CCR5 CCR6 COMT DRD2
2	homeostasis/metabolism	MP:0005376	10.09	ABCB7 BCHE BDNF CCR5 CCR6 COMT
3	behavior/neurological	MP:0005386	9.8	BDNF CCR5 COMT DRD2 DRD3 GABRA2
4	integument	MP:0010771	9.32	BDNF CYP2D6 DRD2 GABRA2 OPRM1 PRL

Sources

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 380)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Olanzapine

Approved, Investigational

Phase 4

132539-06-1

135398745 4585

Valproic acid

Approved, Investigational

Phase 4

99-66-1

3121

Sofosbuvir

Approved

Phase 4

1190307-88-0

45375808

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 4

55-56-1

2713 9552079

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Risperidone

Approved, Investigational

Phase 4

106266-06-2

5073

Fluoxetine

Approved, Vet_approved

Phase 4

54910-89-3

3386

Paroxetine

Approved, Investigational

Phase 4

61869-08-7

43815

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 4

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Desipramine

Approved, Investigational

Phase 4

50-47-5

2995

Carbamazepine

Approved, Investigational

Phase 4

298-46-4

2554

Amantadine

Approved

Phase 4

768-94-5

2130

Velpatasvir

Approved, Investigational

Phase 4

1377049-84-7

77335690 67683363

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

581 12035

Diazepam

Approved, Illicit, Investigational, Vet_approved

Phase 4

439-14-5

3016

Brexpiprazole

Approved, Investigational

Phase 4

913611-97-9

11978813

Ampicillin

Approved, Vet_approved

Phase 4

69-53-4

6249

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Vancomycin

Approved

Phase 4

1404-90-6

14969

Cephalexin

Approved, Investigational, Vet_approved

Phase 4

15686-71-2

27447

Ceftriaxone

Approved

Phase 4

73384-59-5

5479530

Ceftaroline fosamil

Approved, Investigational

Phase 4

229016-73-3

72562361

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Cefepime

Approved, Investigational

Phase 4

88040-23-7

5479537

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Linezolid

Approved, Investigational

Phase 4

165800-03-3

441401

Daptomycin

Approved, Investigational

Phase 4

103060-53-3

16129629

Rifampicin

Approved

Phase 4

13292-46-1

135512673 5381226 135900090

Dicloxacillin

Approved, Investigational, Vet_approved

Phase 4

3116-76-5

18381

Oxacillin

Approved, Investigational

Phase 4

66-79-5

6196

Oritavancin

Approved, Investigational

Phase 4

171099-57-3

16136912

Progesterone

Approved, Vet_approved

Phase 4

57-83-0

5994

Cocaine

Approved, Illicit

Phase 4

50-36-2

446220 5760

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Methadone

Approved

Phase 4

76-99-3, 1095-90-5

4095

Diamorphine

Approved, Illicit, Investigational

Phase 4

561-27-3

5462328

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Clozapine

Approved

Phase 4

5786-21-0

2818 135398737

Oxytocin

Approved, Vet_approved

Phase 4

50-56-6

439302 53477758

Trazodone

Approved, Investigational

Phase 4

19794-93-5

5533

Oxymorphone

Approved, Investigational, Vet_approved

Phase 4

76-41-5

5284604

Cysteine

Approved, Nutraceutical

Phase 4

52-90-4

594 5862

Anti-Infective Agents, Local

Phase 4

Liver Extracts

Phase 4

interferons

Phase 4

Respiratory System Agents

Phase 4

Serotonin 5-HT1 Receptor Agonists

Phase 4

Antimetabolites

Phase 4

Interventional clinical trials:

(show top 50) (show all 1677)

#	Name	Status	NCT ID	Phase	Drugs
1	Cognitive Correlates of Substance Abuse, Part 1	Unknown status	NCT00000346	Phase 4
2	Intravenous Lidocaine for Perioperative and Postoperative Analgesia	Unknown status	NCT03921567	Phase 4	Lidocaine Hydrochloride;Lidocaine Hydrochloride and Ketamine;Placebo
3	Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder	Unknown status	NCT03857581	Phase 4	Clozapine;Olanzapine
4	Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents	Unknown status	NCT00536419	Phase 4	Methylphenidate
5	Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder	Unknown status	NCT02477280	Phase 4	Methylphenidate;Placebo
6	A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users	Unknown status	NCT02192931	Phase 4	Creatine monohydrate
7	Translating Depression Guidelines Into Substance Abuse Treatment	Completed	NCT00137306	Phase 4
8	A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse	Completed	NCT00223197	Phase 4	Pregnenolone
9	Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse	Completed	NCT00208169	Phase 4	Aripiprazole
10	Depakote ER Therapy for Mania Comorbid With Substance Abuse	Completed	NCT00208195	Phase 4	Divalproex ER
11	Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment	Completed	NCT00844272	Phase 4
12	A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program	Completed	NCT03093415	Phase 4	elbasvir-grazoprevir (50 mg/100 mg)
13	People Who Inject Drugs; Longitudinal Staphylococcus Aureus Colonization Pattern and the Impact on Infection Frequency by Regular Showers With Chlorhexidine	Completed	NCT03940729	Phase 4	Chlorhexidine Topical
14	Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)	Completed	NCT00798538	Phase 4
15	Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training®	Completed	NCT00484692	Phase 4	sustained-release bupropion (Zyban(R))
16	Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia	Completed	NCT00156715	Phase 4	Quetiapine
17	Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)	Completed	NCT00130923	Phase 4	Risperidone Long Acting;oral risperidone
18	Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone	Completed	NCT00208143	Phase 4	Quetiapine;Risperidone
19	Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder	Completed	NCT00203528	Phase 4	divalproex sodium ER;risperidone
20	Creatine as a Treatment Option for Depression in Methamphetamine Using Females	Completed	NCT01514630	Phase 4	Creatine monohydrate
21	Abuse Liability of Controlled-Release Oxycodone Formulations	Completed	NCT02101840	Phase 4	Apo-Oxycodone CR®;OxyNEO®;Placebo
22	Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO)	Completed	NCT01936857	Phase 4	Buprenorphine/naloxone;Methadone Maintenance Therapy
23	Drug Contextual Conditioning With in Humans: Causes and Consequences	Completed	NCT03075501	Phase 4	Stimulant or sedative;Placebo
24	Substance Dependent Teens - Impact of Treating Depression Study 1	Completed	NCT00061113	Phase 4	Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
25	Pharmacotherapy and Intensive Treatment	Completed	NCT00000218	Phase 4	Carbamazepine
26	Relapse Prevention With Varenicline	Completed	NCT00944554	Phase 4	Varenicline;Placebo
27	Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks	Completed	NCT00194480	Phase 4	Pegylated Interferon
28	Brain Changes in Stimulant Dependent Subjects	Completed	NCT00000343	Phase 4
29	Methamphetamine Abuse Pharmacology in Patients With AIDS	Completed	NCT00000321	Phase 4	Desipramine
30	Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study	Completed	NCT00015340	Phase 4	Buprenorphine/naloxone
31	Methylphenidate Raclopride PET Test	Completed	NCT00015301	Phase 4	Methylphenidate
32	Pathophysiological Subtyping of Abnormalities in Cocaine Dependence	Completed	NCT00015275	Phase 4
33	Modeling Impaired Judgement in Cocaine Abusers	Completed	NCT00015236	Phase 4
34	Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD)	Completed	NCT00218322	Phase 4	Atomoxetine hydrochloride;Placebo
35	On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings	Completed	NCT00317460	Phase 4
36	Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence	Completed	NCT00232336	Phase 4	quetiapine
37	Multimodal Treatment Study of Children With ADHD	Completed	NCT00000388	Phase 4	Anti-ADHD medication
38	Smoking Cessation Treatment for Methadone Maintenance Patients	Completed	NCT01027754	Phase 4	Varenicline;Placebo
39	VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison	Completed	NCT01563718	Phase 4	naltrexone for extended release injectable suspension
40	Treatment of Polydrug-Using Opiate Dependents During Withdrawal	Completed	NCT00367874	Phase 4	Buprenorphine;Valproate
41	Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy	Completed	NCT00684073	Phase 4	buprenorphine;buprenorphine/naloxone
42	Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use	Completed	NCT03842436	Phase 4	Truvada
43	Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth	Completed	NCT01843023	Phase 4	Extended Release Naltrexone;Buprenorphine
44	Feasibility of Emergency Department Initiated Extended-Release Naltrexone and Case Management Services for the Treatment of Alcohol Use Disorder	Completed	NCT04094584	Phase 4	Vivitrol (Extended Release Naltrexone)
45	Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV	Completed	NCT03057847	Phase 4	Sofosbuvir/Velpatasvir
46	Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers	Completed	NCT00685620	Phase 4
47	Improving Hepatitis C Treatment in Injection Drug Users	Completed	NCT00148031	Phase 4	Pegylated Interferon and Ribavirin
48	A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects	Completed	NCT00605033	Phase 4	Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
49	A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users	Completed	NCT00604188	Phase 4	Suboxone (SCH 000484);Subutex (SCH 028444)
50	A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use	Completed	NCT03998176	Phase 4	Bictegravir/emtricitabine/tenofovir alafenamide

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Desipramine

Desipramine Hydrochloride

Doxapram

Doxapram Hydrochloride

Cochrane evidence based reviews: substance-related disorders

Sources

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

#	Genetic test	Affiliating Genes
1	Substance Abuse ²⁸

Sources

Anatomical Context for Substance Abuse

Organs/tissues related to Substance Abuse:

MalaCards : Brain, Prefrontal Cortex, Cingulate Cortex, Cortex, Eye, Heart, Spinal Cord

Sources

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 25767)

#	Title	Authors	PMID	Year
1	Sleep-mediated regulation of reward circuits: implications in substance use disorders. ⁶²	Guo R...Huang YH	35710601	2023
2	A Pragmatic Clinical Approach to Substance Abuse Prevention. ⁶²	Riggs P	36410897	2023
3	Adaptation of the Devaluation-Discrimination Scale Into Turkish: A Comprehensive Psychometric Analysis. ⁶²	Sahin E...Topkaya N	34459254	2023
4	Depression and Suicidal Behavior in Adolescents. ⁶²	Grossberg A...Rice T	36402497	2023
5	Primary mental healthcare for adults with mild intellectual disabilities: a Dutch database study. ⁶²	Pouls KPM...Leusink GL	36412308	2022
6	Can cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020). ⁶²	Rock KL...Copeland CS	35946604	2022
7	Childhood stress and midlife depression in women: the influence of diet quality. ⁶²	Chiu DT...Laraia BA	34844523	2022
8	Temporal trends and disparities in gastroenterology care use before, during, and after COVID-19 lockdown. ⁶²	Sanaka H...Macaron C	36038149	2022
9	Trends in buprenorphine-waivered providers in Medicaid expansion and non-expansion states by their public listing status. ⁶²	Sanmartin MX...Dwyer DS	35442126	2022
10	Mental health symptom changes in pregnant individuals across the COVID-19 pandemic: a prospective longitudinal study. ⁶²	Gimbel LA...Crowell SE	36463120	2022
11	Clustering of homicide with other adverse health outcomes in the Netherlands. ⁶²	van Breen JA...Liem MCA	36164507	2022
12	Prevalence and risk factors of non-adherence to antipsychotic medications in Saudi Arabia. ⁶²	Alsfouk BA...Alsfouk AA	36458442	2022
13	Effect of Amoxicillin/Clavulanic acid in attenuating Pregabalin-induced Condition Place Preference. ⁶²	Hammad AM...Al-Trad B	36470419	2022
14	Predicting Young Adult Tobacco, Drug and Alcohol Use Among Participants in the CAMP Trial. ⁶²	Annett RD...Bender BG	35013874	2022
15	Childhood Experiences of Companion Animal Abuse and its Co-Occurrence with Domestic Abuse: Evidence from a National Youth Survey in Norway. ⁶²	Muri K...Hafstad GS	35156447	2022
16	Differences Between Sexual and Nonsexual Homicides of Women in the United States: Findings From the National Violent Death Reporting System. ⁶²	De Veauuse Brown NF...Watson AEN	34990564	2022
17	Gender Differences Between Domestic Violent Men and Women: Criminogenic Risk Factors and Their Association With Treatment Dropout. ⁶²	Bijlsma AME...Assink M	34965769	2022
18	[Illicit Drug Exposures Reported to the Poisons Information Centre Erfurt (2011 to 2020)]. ⁶²	Deters M...Prasa D	34598281	2022
19	Getting to the Sandbar: Understanding the Emotional Phases of COVID-19 Among College and University Students. ⁶²	Stowe A...Lanzi RG	34225513	2022
20	Tramadol misuse in treatment-seeking adolescents and young adults with problematic substance use - Prediction of treatment retention. ⁶²	Almer Herrnsdorf E...Hakansson A	35875347	2022
21	Changes in the Risk of Sexual Reoffending: The Role and Relevance of Perceived Self-Efficacy and Adult Attachment Styles in Correctional Treatment. ⁶²	Stuck E...Brunner F	34724856	2022
22	The prevalence of substance abuse and associated factors among male prisoners in Karachi jails, Pakistan. ⁶²	Jamal M...Shakoor A	36212581	2022
23	Analysis of hospital costs by morbidity group for patients with severe mental illness. ⁶²	Caballer-Tarazona V...Reyes-Santias F	35318876	2022
24	Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009-2019. ⁶²	DiNardi M...Kim SY	36457346	2022
25	Signs and symptoms of COVID-19 in patients with multiple sclerosis. ⁶²	Schiavetti I...MuSC-19 Study Group	36086905	2022
26	Social Disparities among Sudden Death victims with HIV. ⁶²	Klein MD...Simpson RJ	35672553	2022
27	Sexually transmitted infections among patients attending a sexual assault centre: a cohort study from Oslo, Norway. ⁶²	Skjalaaen K...Vallersnes OM	36456026	2022
28	Risk factors for comorbid epilepsy in patients with psychogenic non-epileptic seizures. Dataset of a large cohort study. ⁶²	Massot-Tarrus A...Mirsattari SM	36160062	2022
29	Electrophysiological and behavioral correlates of cannabis use disorder. ⁶²	Andriot T...Ros T	35698004	2022
30	Developing a National Trauma Research Action Plan: Results from the long-term outcomes research gap Delphi survey. ⁶²	Herrera-Escobar JP...NTRAP Long-term Outcomes Panel	35972140	2022
31	Association of Adverse Childhood Experiences and Social Isolation With Later-Life Cognitive Function Among Adults in China. ⁶²	Lin L...Guo VY	36367722	2022
32	Impacts of the New York State COVID-19 Disaster Emergency Orders on prescription dispensing for opioids and medication for opioid use disorder. ⁶²	Suri A...Rundle AG	36398540	2022
33	Substance use, mental health and dual disorders on pregnancy: Results of prevalence and treatment rates in a developed country. ⁶²	Carmona Camacho R...Baca-Garcia E	33768264	2022
34	Psychological Reactions to Different Types of Gender-Based Violence in Women Survivors of Violence in the Context of a Developing Country. ⁶²	Akter F...Deeba F	34625007	2022
35	Case report of a phencyclidine false positive due to lamotrigine use with confirmatory testing. ⁶²	Cole J	35961834	2022
36	Parental alcohol and drug abuse and offspring mortality by age 10: a population-based register study. ⁶²	Berg V...Latvala A	36172920	2022
37	Cognitive and Neuropsychiatric Impairment in Dystonia. ⁶²	Bailey GA...Peall KJ	36201146	2022
38	Alcohol, nicotine, and COVID-19: A retrospective study of health outcomes in central Pennsylvania. ⁶²	Xu KL...Randall PA	36442695	2022
39	Sex, Race, Insurance, and Pain: Do Patient Sociodemographics Influence Postoperative Opioid Prescriptions Among Hand Surgeons? ⁶²	Peck CJ...Prsic A	33682465	2022
40	Epidemiological Trend of Esophageal Cancer at a Tertiary Cancer Center in Mumbai, India, Over the Past 15 Years. ⁶²	Noronha V...Badwe R	36418768	2022
41	Association between attention deficit hyperactivity disorder and outcomes after metabolic and bariatric surgery: a nationwide propensity-matched cohort study. ⁶²	Stenberg E...Naslund E	36443212	2022
42	The Role of Gender in the Association between Mental Health and Potentially Preventable Hospitalizations: A Single-Center Retrospective Observational Study. ⁶²	Cedrone F...Di Martino G	36429414	2022
43	Predictors of illicit substance abuse/dependence during young adulthood: A machine learning approach. ⁶²	Rakovski C...de Azevedo Cardoso T	36470198	2022
44	Are trauma surgical societies adequately addressing mental health after injury? ⁶²	Kishawi SK...Ho VP	35981920	2022
45	Characterizing OPRM1 DNA methylation in prescription opioid users with chronic musculoskeletal pain. ⁶²	Sheikh S...Fillingim RB	36447952	2022
46	Transient global amnesia: Uncommon diagnosis of exclusion. ⁶²	Sheikh Hassan M...Adam Mohamed N	36439382	2022
47	Associations between Homelessness and Alzheimer's Disease and Related Dementia: A Systematic Review. ⁶²	Babulal GM...Williams MM	35750476	2022
48	Psychological and physical wellbeing in adults who grew up with a mentally ill parent: A systematic mixed-studies review. ⁶²	Brummelhuis IAM...Videler AC	36471514	2022
49	Movement if Life-Optimizing Patient Access to Total Joint Arthroplasty: Alcohol and Substance Abuse Disparities. ⁶²	Bernstein J...Green T	35442926	2022
50	Impact of Opioid Epidemic on Infective Endocarditis Outcomes in the United States: From the National Readmission Database. ⁶²	Khayata M...Xu B	36085056	2022

Sources

Genes for Substance Abuse

Genes related to Substance Abuse (0 elite genes):

(show top 50) (show all 63)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MIAT	Myocardial Infarction Associated Transcript	RNA Gene	153.44	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	20951849
2	DRD2	Dopamine Receptor D2	Protein Coding	16.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
3	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	16.27	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	16.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	15.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	COMT	Catechol-O-Methyltransferase	Protein Coding	15.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	GABRA2	Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2	Protein Coding	15.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	15.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	DRD3	Dopamine Receptor D3	Protein Coding	14.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	CCR5	C-C Motif Chemokine Receptor 5	Protein Coding	14.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	PRL	Prolactin	Protein Coding	14.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	14.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	BCHE	Butyrylcholinesterase	Protein Coding	14.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	TF	Transferrin	Protein Coding	11.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	ABCB7	ATP Binding Cassette Subfamily B Member 7	Protein Coding	11.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	H2AC18	H2A Clustered Histone 18	Protein Coding	10.04	DISEASES inferred ¹⁴ ¹⁴
17	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	8.32	DISEASES inferred ¹⁴ ¹⁴
18	OPRM1	Opioid Receptor Mu 1	Protein Coding	8.32	DISEASES inferred ¹⁴
19	SERPINA3	Serpin Family A Member 3	Protein Coding	8.12	DISEASES inferred ¹⁴ ¹⁴
20	PRODH	Proline Dehydrogenase 1	Protein Coding	8.05	DISEASES inferred ¹⁴ ¹⁴
21	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	7.94	DISEASES inferred ¹⁴
22	CRH	Corticotropin Releasing Hormone	Protein Coding	7.91	DISEASES inferred ¹⁴
23	MIR199A1	MicroRNA 199a-1	RNA Gene	7.84	DISEASES inferred ¹⁴ ¹⁴
24	MIR9-1	MicroRNA 9-1	RNA Gene	7.84	DISEASES inferred ¹⁴ ¹⁴
25	ADH1B	Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide	Protein Coding	7.82	DISEASES inferred ¹⁴
26	ALDH2	Aldehyde Dehydrogenase 2 Family Member	Protein Coding	7.74	DISEASES inferred ¹⁴
27	CD4	CD4 Molecule	Protein Coding	7.72	DISEASES inferred ¹⁴
28	DRD4	Dopamine Receptor D4	Protein Coding	7.71	DISEASES inferred ¹⁴
29	INS	Insulin	Protein Coding	7.7	DISEASES inferred ¹⁴
30	PDYN	Prodynorphin	Protein Coding	7.67	DISEASES inferred ¹⁴
31	ALB	Albumin	Protein Coding	7.65	DISEASES inferred ¹⁴
32	CRHR1	Corticotropin Releasing Hormone Receptor 1	Protein Coding	7.64	DISEASES inferred ¹⁴
33	CYP2E1	Cytochrome P450 Family 2 Subfamily E Member 1	Protein Coding	7.61	DISEASES inferred ¹⁴
34	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	7.57	DISEASES inferred ¹⁴
35	CRP	C-Reactive Protein	Protein Coding	7.55	DISEASES inferred ¹⁴
36	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	7.47	DISEASES inferred ¹⁴
37	ACE	Angiotensin I Converting Enzyme	Protein Coding	7.46	DISEASES inferred ¹⁴
38	IL6	Interleukin 6	Protein Coding	7.46	DISEASES inferred ¹⁴
39	POMC	Proopiomelanocortin	Protein Coding	7.44	DISEASES inferred ¹⁴
40	MAOA	Monoamine Oxidase A	Protein Coding	7.38	DISEASES inferred ¹⁴
41	OGN	Osteoglycin	Protein Coding	7.38	DISEASES inferred ¹⁴
42	CNR1	Cannabinoid Receptor 1	Protein Coding	7.37	DISEASES inferred ¹⁴
43	ANKK1	Ankyrin Repeat And Kinase Domain Containing 1	Protein Coding	7.35	DISEASES inferred ¹⁴
44	OXT	Oxytocin/Neurophysin I Prepropeptide	Protein Coding	7.34	DISEASES inferred ¹⁴
45	TNF	Tumor Necrosis Factor	Protein Coding	7.2	DISEASES inferred ¹⁴
46	MIR181B1	MicroRNA 181b-1	RNA Gene	7.18	DISEASES inferred ¹⁴ ¹⁴
47	DRD1	Dopamine Receptor D1	Protein Coding	7.15	DISEASES inferred ¹⁴
48	GRIN2B	Glutamate Ionotropic Receptor NMDA Type Subunit 2B	Protein Coding	7.11	DISEASES inferred ¹⁴
49	OPRK1	Opioid Receptor Kappa 1	Protein Coding	7.1	DISEASES inferred ¹⁴
50	IL1B	Interleukin 1 Beta	Protein Coding	7.07	DISEASES inferred ¹⁴

Sources

Variations for Substance Abuse

Sources

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Sources

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Tamoxifen metabolism ⁷⁴ Show member pathways Phenytoin Pathway, Pharmacokinetics ⁶⁰	11.06	CYP2D6 CYP2C19 COMT
2	Neurotransmitter clearance ⁶⁶ Show member pathways Dopamine clearance from the synaptic cleft ⁶⁶ Enzymatic degradation of dopamine by COMT ⁶⁶ Enzymatic degradation of Dopamine by monoamine oxidase ⁶⁶ Flavan-3-ol metabolic pathway ⁷⁴ Metabolism of serotonin ⁶⁶ Serotonin clearance from the synaptic cleft ⁶⁶	10.65	SLC6A4 SLC6A3 COMT BCHE
3	Venlafaxine Pathway, Pharmacokinetics ⁶⁰ Show member pathways Citalopram and Escitalopram Pathway, Pharmacokinetics ⁶⁰ Defective SLC6A2 causes orthostatic intolerance (OI) ⁶⁶ Lansoprazole Pathway, Pharmacokinetics ⁶⁰ Omeprazole and Esomeprazole Pathway, Pharmacokinetics ⁶⁰	10.56	SLC6A4 CYP2D6 CYP2C19
4	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	10.38	SLC6A4 SLC6A3 DRD3 DRD2 COMT

Sources

GO Terms for Substance Abuse

Cellular components related to Substance Abuse according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005887	10.23	CCR5 CCR6 DRD2 DRD3 GABRA2 OPRM1
2	plasma membrane	GO:0005886	10.23	CCR5 CCR6 DRD2 DRD3 GABRA2 OPRM1
3	axon	GO:0030424	10.15	SLC6A3 OPRM1 GABRA2 DRD2 COMT BDNF
4	presynaptic membrane	GO:0042734	9.72	SLC6A4 SLC6A3 OPRM1 DRD2
5	postsynaptic membrane	GO:0045211	9.65	SLC6A4 SLC6A3 OPRM1 GABRA2 DRD2
6	obsolete integral component of presynaptic membrane	GO:0099056	9.26	SLC6A4 SLC6A3 OPRM1 DRD2
7	obsolete integral component of postsynaptic membrane	GO:0099055	8.92	SLC6A4 SLC6A3 OPRM1 DRD2

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to xenobiotic stimulus	GO:0009410	10.11	SLC6A4 SLC6A3 DRD3 DRD2 BCHE
2	neurotransmitter transport	GO:0006836	10.02	SLC6A4 SLC6A3 GABRA2
3	hyaloid vascular plexus regression	GO:1990384	9.86	SLC6A3 DRD2
4	dopamine uptake involved in synaptic transmission	GO:0051583	9.84	SLC6A3 DRD2
5	monoterpenoid metabolic process	GO:0016098	9.83	CYP2D6 CYP2C19
6	response to ethanol	GO:0045471	9.83	DRD2 DRD3 OPRM1 SLC6A3
7	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.81	DRD2 DRD3
8	regulation of potassium ion transport	GO:0043266	9.8	DRD2 DRD3
9	regulation of dopamine uptake involved in synaptic transmission	GO:0051584	9.78	DRD2 DRD3
10	acid secretion	GO:0046717	9.71	DRD3 DRD2
11	response to histamine	GO:0034776	9.67	DRD3 DRD2
12	response to morphine	GO:0043278	9.65	OPRM1 DRD3 DRD2
13	dopamine metabolic process	GO:0042417	9.63	DRD3 DRD2 COMT
14	regulation of locomotion involved in locomotory behavior	GO:0090325	9.62	DRD3 DRD2
15	prepulse inhibition	GO:0060134	9.43	SLC6A3 DRD3 DRD2
16	response to cocaine	GO:0042220	9.23	SLC6A3 OPRM1 DRD3 DRD2

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	dopamine binding	GO:0035240	9.46	SLC6A3 DRD2
2	dopamine neurotransmitter receptor activity	GO:0004952	8.96	DRD3 DRD2
3	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	8.92	DRD3 DRD2